Glucovans Tablets p/o 500mg/2.5mg №15×2: Effective Diabetes Management with Metformin and Glibenclamide
Description:
Glucovans tablets p/o 500mg/2.5mg №15×2 is a fixed-dose combination medication containing metformin and glibenclamide, both oral hypoglycemic agents. This medication is indicated for the treatment of type 2 diabetes mellitus in adults, particularly those who haven’t achieved desired blood sugar control with diet, exercise, or monotherapy with metformin or a sulfonylurea derivative.
How Glucovans Works:
- Metformin: A biguanide that reduces both basal and postprandial glucose levels by suppressing hepatic glucose production, improving insulin sensitivity, and slowing glucose absorption.
- Glibenclamide: A second-generation sulfonylurea derivative that stimulates insulin release from pancreatic beta cells.
Benefits of Glucovans:
- Synergistic effect: The combined action of metformin and glibenclamide provides a more effective blood glucose control compared to individual treatments.
- Improved lipid profile: Metformin helps reduce total cholesterol, LDL, and triglyceride levels, offering additional cardiovascular benefits.
Important Considerations:
- Hypoglycemia risk: Glibenclamide can cause hypoglycemia, especially if meals are delayed, carbohydrate intake is insufficient, or alcohol is consumed.
- Lactic acidosis: Metformin can rarely lead to lactic acidosis, particularly in patients with severe renal insufficiency.
- Renal function monitoring: Regular monitoring of renal function is crucial as metformin is excreted by the kidneys.
- Pregnancy and breastfeeding: Glucovans is contraindicated during pregnancy and breastfeeding.
- Drug interactions: Glucovans can interact with several medications, so it is essential to inform your doctor about all the medications you are taking.
Dosage and Administration:
The dosage of Glucovans is individually tailored by a healthcare professional based on blood glucose levels. It is typically taken once daily with meals.
Side Effects:
Common side effects include nausea, vomiting, diarrhea, abdominal pain, and metallic taste. Less common but serious adverse effects include hypoglycemia, lactic acidosis, and liver problems.
Storage:
Store Glucovans tablets at room temperature, out of reach of children.
Note: This information is for general knowledge and informational purposes only, and does not constitute medical advice. It is crucial to consult with your healthcare provider for diagnosis and treatment of diabetes.
Keywords:
Glucovans, type 2 diabetes, metformin, glibenclamide, hypoglycemia, lactic acidosis, renal function, drug interactions, dosage, side effects, storage, diabetes management, blood sugar control, healthcare provider.
| INN | METFORMIN+GLIBENCLAMIDE |
|---|---|
| The code | 25 210 |
| Barcode | 3 596 540 060 354 |
| Dosage | 500mg/2.5mg |
| Active substance | Metformin, glibenclamide |
| Manufacturer | Merck Sante s.a.s., France |
| Indications Applications | Type 2 diabetes mellitus in adults: with the ineffectiveness of diet therapy, exercise and previous monotherapy with metformin or a sulfonylurea derivative; to replace previous therapy with two drugs (metformin and a sulfonylurea derivative) in patients with stable and well-controlled glycemic levels. |
| Contraindications | hypersensitivity to metformin, glibenclamide or other sulfonylurea derivatives, as well as to excipients; type 1 diabetes; diabetic ketoacidosis; diabetic precoma, diabetic coma; renal failure or impaired renal function (CC <60 ml / min); acute conditions that can lead to a change in kidney function: dehydration, severe infection, shock, intravascular administration of iodine-containing contrast agents; acute or chronic diseases that are accompanied by tissue hypoxia: heart or respiratory failure, recent myocardial infarction, shock; liver failure; porphyria; pregnancy, breastfeeding period; concomitant use of miconazole; extensive surgical operations; chronic alcoholism, acute alcohol intoxication; lactic acidosis (including history); adherence to a hypocaloric diet (less than 1000 cal / day); It is not recommended to use the drug in patients over the age of 60 who perform heavy physical work, which is associated with an increased risk of developing lactic acidosis in them. Glucovance® contains lactose, therefore its use is not recommended in patients with rare hereditary problems of galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome. With caution: febrile syndrome, adrenal insufficiency, hypofunction of the anterior pituitary gland, thyroid disease with uncompensated dysfunction. |
| Side effects | The following side effects may occur during treatment with Glucovance®. The frequency of side effects of the drug is regarded as follows: very common: (≥1/10) frequent: (≥1/100, <1/10) infrequent: (≥1/1000, <1/100) rare: (≥1/10 0, <1/1000) very rare: (≤1/10, 000) isolated cases (cannot be assessed with available data). Metabolic disorders Hypoglycemia; rarely – attacks of hepatic porphyria and skin porphyria; very rarely – lactic acidosis. Decreased absorption of vitamin B12, accompanied by a decrease in its concentration in the blood serum with prolonged use of metformin. When megaloblastic anemia is detected, the possibility of such an etiology must be considered. Disulfiram-like reaction when drinking alcohol. Circulatory and lymphatic systems These adverse events disappear after discontinuation of the drug. Rarely – leukopenia and thrombocytopenia; very rarely – agranulocytosis, hemolytic anemia, bone marrow aplasia and pancytopenia. Gastrointestinal disorders Very common – nausea, vomiting, diarrhea, abdominal pain and lack of appetite. These symptoms are more common at the beginning of treatment and in most cases go away on their own. To prevent the development of these symptoms, it is recommended to take the drug in 2 or 3 doses; slowly increasing the dose of the drug also improves its tolerability. Hepatobiliary disorders Very rarely – a violation of liver function tests or hepatitis, requiring discontinuation of treatment. Nervous system Often – a violation of taste (metallic taste in the mouth). Vision At the beginning of treatment, temporary visual impairment may occur due to a decrease in blood glucose. Skin and subcutaneous tissue Rarely – skin reactions such as itching, urticaria, maculopapular rash. Very rarely – skin or visceral allergic vasculitis, erythema multiforme, exfoliative dermatitis, photosensitivity. Immunological reactions Very rarely – anaphylactic shock. Cross-hypersensitivity reactions to sulfonamides and their derivatives may occur. Laboratory indicators: infrequently – an increase in the concentration of urea and creatinine in the blood serum from an average to moderate degree; very rarely – hyponatremia. |
| Use during pregnancy and lactation | Forbidden to use |
| Application Gender | Any |
| Release Form | tablets |
| Main Active Substances | metformin glibenclamide |
| Composition Means | glibenclamide 2.5 mg metformin hydrochloride 500 mg Excipients: croscarmellose sodium – 14 mg, povidone K30 – 20 mg, microcrystalline cellulose – 56.5 mg, magnesium stearate – 7 mg. Shell composition: Opadry OY-L-24808 pink – 12 mg (lactose monohydrate – 36%, hypromellose 15cP – 28%, titanium dioxide – 24.39%, macrogol – 10%, yellow iron oxide – 1.3%, red iron oxide – 0.3%, iron oxide black – 0.01%), purified water – qs |
| Importer | IOOO Interfarmaks 223028 Minsk region, Minsk district, Zhdanovichsky s / s, ag. Zhdanovichi, st. Star, 19a-5, room. 5-2 |
Related products
